Skip to main content
APGE
NASDAQ Life Sciences

Apogee Secures Exclusive Worldwide License for IL-31R Antibody Target

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$133.2
Mkt Cap
$6.814B
52W Low
$34.34
52W High
$95.315
52W Position info
288% above low
Off High info
at 52W high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

APGE has more than doubled off its 52-week low of $34.34 on elevated volume (2.0× avg).

Summary

Apogee Therapeutics has expanded its drug pipeline by securing an exclusive, worldwide license for an IL-31R antibody target from Paragon Therapeutics, with potential milestones up to $23.25 million. This strategic move, which diversifies its portfolio, occurs as the company's stock trades above its 52-week high and amidst reports of a potential $10.9 billion acquisition by AbbVie.


Key Events · M&A and Partnerships · APGE

  • New Antibody Discovery Agreement

    Apogee Therapeutics entered into an antibody discovery agreement with Paragon Therapeutics, Inc. to generate and characterize monospecific antibody candidates directed to interleukin 31 receptor (IL-31R).

  • Exclusive Worldwide License Granted

    Apogee secured an exclusive, worldwide, royalty-bearing, sublicensable right and license for antibodies discovered under the agreement, targeting the IL-31R target.

  • Development Milestones Established

    The agreement includes potential milestone payments up to $23.25 million, with an initial payment of $5.25 million due upon the first dosing of a human patient in a Phase I trial.

  • Strategic Pipeline Expansion

    This agreement diversifies Apogee's drug pipeline by adding a new, exclusive target (IL-31R) for inflammatory diseases, complementing its existing lead asset.


Analysis · APGE · Life Sciences

This 8-K announces a new strategic partnership and licensing agreement that significantly expands Apogee Therapeutics' drug pipeline. The company has secured an exclusive, worldwide license for antibodies targeting IL-31R, a key receptor in inflammatory diseases. This move diversifies Apogee's portfolio beyond its lead asset, zumilokibart, which recently showed positive Phase 2 results. While the milestone payments of up to $23.25 million are modest relative to Apogee's market capitalization, the addition of a new, exclusive target is a material positive development for a clinical-stage biotech. This news is particularly relevant given recent reports of a potential $10.9 billion acquisition of Apogee by AbbVie, and the company's stock currently trading above its 52-week high, reflecting strong investor confidence.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APGE was trading at $133.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $34.34 to $95.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APGE - Latest Insights

APGE
Sep 03, 2026, 8:53 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $135.11
Real-time Price: $135.11 info
Change: $0 (0%) info
Market Cap: $10.223B info
APGE
Aug 11, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $134.69
Real-time Price: $135.11 info
Change: +$0.420 (+0.31%) info
Market Cap: $10.223B info
APGE
Aug 10, 2026, 7:52 AM EDT
Filing Type: 10-Q
Importance Score:
10
Price at Filing: $134.62
Real-time Price: $135.11 info
Change: +$0.486 (+0.36%) info
Market Cap: $10.223B info
APGE
Aug 10, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $134.79
Real-time Price: $135.11 info
Change: +$0.320 (+0.24%) info
Market Cap: $10.223B info
APGE
Aug 06, 2026, 6:31 AM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $134.27
Real-time Price: $135.11 info
Change: +$0.840 (+0.63%) info
Market Cap: $10.223B info